Skip to main content
OpenTrials
Completed

NCT Number: NCT06185127

Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy

Sedation during flexible bronchoscopy (FB) should maintain an adequate respiratory drive, ensure maximum comfort for the patient, and warrant that the objectives of the procedure are achieved. Nevertheless, the optimal sedation method for FB has yet to be established. This study aimed to compare the standard recommended combination of midazolam-fentanyl (MF) with that of dexmedetomidine-ketamine (DK) for patient sedation during FB. Patients subjected to FB were randomly assigned to a DK (n=25) and an MF group (n=25). The primary outcome was the rate of critical desaturation events (arterial oxygen saturation <80% with nasal oxygen supply 2 L/min). Secondary outcomes included sedation depth, hemodynamic complications, adverse events, and patient and bronchoscopist satisfaction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Diseases Anesthesia Diagnosis Disease Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

19 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Naval Hospital

Athens, Attica, 15561, Greece

About this study

Study design and population This randomized controlled trial of adult patients (age >18 years) scheduled for FB was conducted between September 2019 and May 2020 at the Respiratory Medicine Department of Athens Naval Hospital, Greece.

Exclusion criteria

included: known or suspected allergy to any of the study drugs, renal impairment (serum creatinine > 2 mg/dL), hepatic impairment (liver enzymes > 2 times the upper limit of normal), seizure disorders, history of psychosis or bipolar disorder, hemodynamic instability (heart rate - HR < 50 bpm or systolic blood pressure - SBP < 90 mmHg), and critically ill patients. The study protocol was approved by the Ethics Committee of Athens Naval Hospital (act number 296/13.08.2019), and written informed consent was obtained from all participants.

Protocol Demographic data and medical history were reviewed at the presentation, and the vital signs were assessed and recorded.

Eligible patients were then randomly assigned to two groups:

  • DK group: Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion). After the first 15 minutes, a bolus dose of 50 mg ketamine dissolved in 10 ml saline was given. An increase of 0.1 μg/kg in the infusion rate of dexmedetomidine was considered when necessary to optimize the level of sedation.
  • MF group: Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) and fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam and 150 μg of fentanyl were administered.

The depth of sedation was quantified at the onset of drug infusion using the Observer's Assessment of Alertness/Sedation scale; a maximum score of 3 was considered optimal for starting FB. Bolus doses of dexmedetomidine (DK group) and midazolam (MF group) were administered when necessary to maintain the same target score. An anesthesiologist was present throughout the procedure to oversee and monitor the sedation protocol. Only the anesthesiologist and the nurse of the bronchoscopy suite were aware of the sedation regimen. The attending pulmonologist remained blind regarding the sedation protocol until the completion of the bronchoscopist satisfaction questionnaire (see below).

Lidocaine gel was placed at the nostril of entry before the procedure, and lidocaine (4 ml of 2% solution) was sprayed under direct vision through the bronchoscope for vocal cord anesthesia before entering the larynx. All participants (in both the MF and the DK group) were initially premedicated with 2 mg of midazolam for anxiolysis and perioperative amnesia 10 minutes before commencing the procedure. They also received oxygen at 2 L/min via nasal cannula and 0.9 NaCl i.v. at 8 ml/h throughout the procedure. Continuous monitoring included electrocardiography, oxygen saturation (SpO2), and automated non-invasive blood pressure recordings.

Outcomes The depth of sedation was evaluated using the Ramsay sedation scale [28] and the Riker sedation-agitation scale. Both tools provide quantitative measurements in the maximum and minimum sedation-agitation range during the procedure. Higher Ramsay and lower Riker scores signify deeper sedation levels.

Bronchoscopist satisfaction was measured with a Likert-scale tool answering the question "How satisfied are you with both the ease and outcome of the procedure?" as follows: 1 = not satisfied at all; 2 = somewhat satisfied; 3 = more satisfied with the procedural outcome; 4 = mostly satisfied with the outcome and somewhat with procedural ease; 5 = exceptionally satisfied with both procedural outcome and ease.

Patient satisfaction was evaluated by a short, custom-made questionnaire that included the following questions: 1) I was satisfied with the sedation administered for the procedure, 2) I felt pain and/or discomfort beyond my tolerance during the procedure, 3) I believe my needs were met during the procedure 4) I felt pain and discomfort after the procedure, 5) I would be willing to undergo a second procedure if the first did not yield adequate results. The responses were measured in a Likert scale format with values 1 = strongly disagree; 2 = disagree; 3 = neither agree nor disagree; 4 = agree; 5 =strongly agree. Questions 2 and 4 were scored reversely. The questionnaire was given in printed form at discharge, and the responses were collected by telephone call the day after the procedure.

Sample size estimation and statistical analyses The primary endpoint of the study was the occurrence of major desaturation events (i.e., SpO2 <80% with nasal oxygen supply 2 L/min). Assuming a desaturation rate of 20 ± 5%, we calculated a lower critical number of 25 patients per group to prove non-inferiority within the above limits of the primary endpoint, with a p-value of <0.05 and 85% power.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients scheduled for flexible bronchoscopy at the Naval Hospital of Athens
  • Written informed consent

Exclusion criteria

  • known or suspected allergy to any of the study drugs
  • renal impairment (serum creatinine > 2 mg/dL)
  • hepatic impairment (liver enzymes > 2 times the upper limit of normal)
  • seizure disorders
  • history of psychosis or bipolar disorder
  • hemodynamic instability (heart rate - HR < 50 bpm or systolic blood pressure - SBP < 90 mmHg)
  • critically ill patients.

Treatment and study plan

Dexmedetomidine

Drug

Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).

Other names: Dexmedetomidine administration

ketamine

Drug

A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.

Other names: Ketamine administration

midazolam

Drug

Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.

Other names: Midazolam administration

Fentanyl

Drug

Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.

Other names: Fentanyl administration

Primary outcomes

  1. Depth of sedation Ramsay

    Time frame: Minute 10 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  2. Depth of sedation Ramsay

    Time frame: Minute 20 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  3. Depth of sedation Ramsay

    Time frame: Minute 30 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  4. Depth of sedation Ramsay

    Time frame: Minute 40 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  5. Depth of sedation Ramsay

    Time frame: Minute 50 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  6. Depth of sedation Ramsay

    Time frame: Minute 60 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  7. Depth of sedation Ramsay

    Time frame: Minute 70 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  8. Depth of sedation Ramsay

    Time frame: Minute 80 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  9. Depth of sedation Ramsay

    Time frame: Minute 90 of procedure

    Assessed by Ramsay sedation scale that divides a patient's level of sedation into six categories ranging from severe agitation to deep coma. (https://www.msdmanuals.com/professional/multimedia/table/the-ramsay-sedation-scale; doi:10.1136/bmj.2.5920.656)

  10. Depth of sedation Riker

    Time frame: Minute 10 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  11. Depth of sedation Riker

    Time frame: Minute 20 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  12. Depth of sedation Riker

    Time frame: Minute 30 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  13. Depth of sedation Riker

    Time frame: Minute 40 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  14. Depth of sedation Riker

    Time frame: Minute 50 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  15. Depth of sedation Riker

    Time frame: Minute 60 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  16. Depth of sedation Riker

    Time frame: Minute 70 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  17. Depth of sedation Riker

    Time frame: Minute 80 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  18. Depth of sedation Riker

    Time frame: Minute 90 of procedure

    Assessed by Riker's Sedation-Agitation Scale that ranges from 1 to 7, with scores of <4 indicating deeper sedation, a score of 4 indicating an appearance of calm and cooperativeness, and scores of ≥5 indicating increasing agitation. (https://www.msdmanuals.com/professional/multimedia/table/riker-sedation-agitation-scale; Crit Care Med. 1999;27:1325-1329)

  19. Bronchoscopist satisfaction

    Time frame: 1 hour after the end of the procedure

    Bronchoscopist satisfaction was measured with a Likert-scale tool answering the question "How satisfied are you with both the ease and outcome of the procedure?" as follows: 1 = not satisfied at all; 2 = somewhat satisfied; 3 = more satisfied with the procedural outcome; 4 = mostly satisfied with the outcome and somewhat with procedural ease; 5 = exceptionally satisfied with both procedural outcome and ease.

  20. Patient satisfaction

    Time frame: 24 hours after bronchoscopy

    Patient satisfaction was evaluated by a short, custom-made questionnaire that included the following questions: 1) I was satisfied with the sedation administered for the procedure, 2) I felt pain and/or discomfort beyond my tolerance during the procedure, 3) I believe my needs were met during the procedure 4) I felt pain and discomfort after the procedure, 5) I would be willing to undergo a second procedure if the first did not yield adequate results. The responses were measured in a Likert scale format with values 1 = strongly disagree; 2 = disagree; 3 = neither agree nor disagree; 4 = agree; 5 =strongly agree. Questions 2 and 4 were scored reversely.

Sponsors and collaborators

Lead sponsor

University of Patras

Other

Registry information

Official study title

Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam for Patient Sedation During Flexible Bronchoscopy: a Prospective, Single-blind, Randomized Controlled Trial

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Dec 29, 2023
Registry last updated
Dec 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.